A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma.

Trial Profile

A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Melphalan (Primary) ; Cyclophosphamide; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Primary endpoint (For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first (preplanned second interim analysis-66% of the events)) has been met, according to results of preplanned second interim analysis (July 2017), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results of preplanned second interim analysis (July 2017), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results of a pre-specified analysis comparing ASCT-1 and ASCT-2 arms (n=415), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top